bosentan anhydrous has been researched along with Cirrhoses, Experimental Liver in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballas, K; Emoniotou, E; Kalodimos, G; Koukoulis, G; Marakis, G; Papamichali, R; Pavlidis, T; Psarras, K; Rafailidis, S; Sakadamis, A | 1 |
| Clemens, MG; Karaa, A; Keller, S; Paxian, M; Zhang, JX | 1 |
| Bauer, C; Diekmann, F; Distler, A; Gross, P; Hocher, B; Neumayer, HH; Rohmeiss, P; Zart, R | 1 |
| Chung, JJ; Rockey, DC | 1 |
| Cailmail, S; Calmus, Y; Clozel, M; Gadano, A; Gomola, A; Lebrec, D; Moreau, R; Sogni, P | 1 |
| Chagneau, C; De Gottardi, A; Fléjou, JF; Fouassier, L; Housset, C; Lahaye, P; Lebrec, D; Moreau, R; Reichen, J; Rona, JP; Tazi, KA | 1 |
6 other study(ies) available for bosentan anhydrous and Cirrhoses, Experimental Liver
| Article | Year |
|---|---|
Effect of early bosentan administration on the development of esophageal varices in cirrhotic rats: experimental study in Wistar rats.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal and Gastric Varices; Follow-Up Studies; Liver; Liver Cirrhosis, Experimental; Male; Portal Pressure; Rats; Rats, Wistar; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Inhibition of endothelin-1-mediated up-regulation of iNOS by bosentan ameliorates endotoxin-induced liver injury in cirrhosis.
Topics: Alanine Transaminase; Animals; Antihypertensive Agents; Bosentan; Cyclooxygenase 2; Disease Models, Animal; DNA Primers; Endothelins; Endotoxins; Gene Expression Regulation, Enzymologic; Lipopolysaccharides; Liver; Liver Cirrhosis, Experimental; Male; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides | 2006 |
Paracrine renal endothelin system in rats with liver cirrhosis.
Topics: Animals; Bosentan; Carbon Tetrachloride; Endothelin Receptor Antagonists; Endothelins; Glomerular Filtration Rate; Kidney Medulla; Liver Cirrhosis, Experimental; Male; Rats; Rats, Inbred WKY; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Sulfonamides | 1996 |
Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing.
Topics: Actins; Animals; Bosentan; Cell Differentiation; Cells, Cultured; Collagen; Endothelins; Extracellular Matrix; Fibronectins; Immunoblotting; Immunohistochemistry; Liver; Liver Cirrhosis, Experimental; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Vasoconstrictor Agents; Viper Venoms; Wound Healing | 1996 |
Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides | 1998 |
Endothelium-dependent blunted membrane potential responses to ATP-sensitive K+ channel modulators in aortae from rats with cirrhosis.
Topics: Adenosine Triphosphate; Animals; Aorta; Bosentan; Cromakalim; Diazoxide; Endothelin-1; Endothelium, Vascular; Glyburide; Liver Cirrhosis, Experimental; Male; Membrane Potentials; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Sprague-Dawley; Sulfonamides; Tolbutamide | 1999 |